Plasma tumor necrosis factor-α, its soluble receptors and interleukin-1β levels in critically burned patients

Burns

Volumn 24, Issue 7, 1998, Pages 599-603

  Zhang, B ^a   Huang, Y H ^a   Chen, Y ^a   Yang, Y ^a   Hao, Z L ^a   Xie, S L ^a  

^a Burn Center   (China)

Author keywords

Burns; Interleukin 1 ; Multiple organ dysfunction syndrome; Sepsis; Soluble TNF receptor; Tumor necrosis factor

Indexed keywords

INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BURN; BURN SHOCK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPOVOLEMIC SHOCK; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; NORMAL HUMAN; PATHOGENESIS; SEPSIS;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; BIOLOGICAL MARKERS; BURNS; CRITICAL ILLNESS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTERLEUKIN-1; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SEPSIS; SHOCK, TRAUMATIC; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032214827     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-4179(98)00091-6     Document Type: Article

References (31)

1. Marano M.A., Fong Y., Moldawer L.L.et al. Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obste. 170:1990;32-38.
2. De Bandt J.P., Chollet-Martin S., Hernvann A.et al. Cytokine response to burn injury: relationship with protein metabolism. J Trauma. 36:1994;624-628.
3. Endo S., Inada K., Yamada Y.et al. Plasma tumor necrosis factor-α (TNF-α) levels in patients with burns. Burns. 19:1993;124-127.
4. Drost A.C., Burleson D.G., Cioffi W.G.et al. Plasma cytokines following thermal injury and their relationship with patient mortality, burn size, and time postburn. J Trauma. 35:1993;335-339.
5. Drost A.C., Burleson D.G., Cioffi W.G.et al. Plasma cytokines after thermal injury and their relationship to infection. Ann Surn. 218:1993;74-78.
6. Liu X.S., Yang Z.C., Luo Z.H.et al. A preliminary exploration of the relationship between tumor necrosis factor (TNF) and monocytic in vitro production of interleukin-1 (IL-1) and internal organ dysfunction in severely burned patients. Burns. 21:1995;29-33.
7. Yamada Y., Endo S., Inada K. Plasma cytokine levels in patients with severe burn injury-with reference to the relationship between infection and prognosis. Burns. 22:1996;587-593.
8. Sheng Z.Y., Yao Y.M., Yu Y. The relationship between gut-derived endotoxemia and tumor necrosis factor, neoptein: experimental and clinical studies. Chin Med J. 110:1997;30-35.
9. Yeh F.L., Lin W.L., Shen H.D.et al. Changes in serum tumor necrosis factor-α in burned patients. Burns. 23:1997;6-10.
10. Liu X.S., Yang Z.C., Luo Z.H., Li A.N. Clinical significance of the change of blood monocytic interleukin-1 production in vitro in severely burned patients. Burns. 20:1994;302-306.
11. Wogesen L., Jensen M., Svensson P.et al. Pancreatic beta-cell function and interleukin-1β in plasma during the acute phase response in patients with major burn injuries. Eur J Clin Invest. 23:1993;311-319.
12. Mandrup-Poulsen T., Wogensen L.D., Jensen M.et al. Circulating interleukin-1 receptor antagonist concentrations are increased in adult patients with thermal injury. Crit Care Med. 23:1995;26-33.
13. Strieter R.M., Kunkel S.L., Bone R.C. Role of tumor necrosis factor-α in disease states and inflammation. Crit Care Med. 21:1993;S447-S463.
14. Brouckaert P., Libert C., Everaerut B.et al. Tumor necrosis factor, its receptors and the connection with interleukin-1 and interleukin-6. Immunbiology. 187:1993;317-329.
15. Borrelli E., Roux-Lombard P., Grau G.E.et al. Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med. 24:1996;329-397.
16. Adolf G.R., Apfler I. A monoclonal antibody-based enzyme immunoassay for quantitation of human tumor necrosis factor binding protein I, a soluble fragment of the 60 kDa TNF receptor, in biological fluids. J Immuno Methods. 143:1991;127-136.
17. Accp/sccm Consensus Conference Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 101:1992;1644-1655.
18. Deitch E.A. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg. 216:1992;117-134.
19. Goris R.J.A., te Boekhorst T.P.A., Nuytinck J.K.S.et al. Multiple organ failure. Generalized autodestructive inflammation? Arch Surg. 120:1985;1109-1115.
20. Okuaswa S., Gelfand J.A., Ikejima T.et al. Interleukin-1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 81:1988;1162-1172.
21. Barriere S.L., Lowry S.F. An overview of mortality risk prediction in sepsis. Crit Care Med. 23:1995;376-393.
22. Pinsky M.R., Vincent J.L., Deviere J.et al. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest. 103:1993;565-575.
23. Cannon J.G., Friedberg J.S., Gelfand J.A.et al. Circulating interleukin-1β and tumor necrosis factor-concentrations after burn injury in humans. Crit Care Med. 20:1992;1414-1419.
24. Goldie A.S., Fearon K.C., Ross J.A.et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA. 274:1995;172-177.
25. Schroder J., Stuber F., Gallati H.et al. Pattern of soluble TNF receptors I and II in sepsis. Infection. 23:1995;143-148.
26. Calvano S.E., van der Poll T., Coyle S.M.et al. Monocyte tumor necrosis factor receptor levels as a predictor of risk in human sepsis. Arch Surg. 131:1996;434-437.
27. Seckinger P., Isaaz S., Dayer J.M. A human inhibitor of TNF-α J Exp Med. 167:1988;1511-1516.
28. Aderka D., Engelmann H., Maor Y.et al. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 175:1992;323-329.
29. Mohler K.M., Torrance D.S., Smith C.A.et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 151:1993;1548-1561.
30. Giroir B.P., Horton J.W., Jean White D.et al. Inhibition of tumor necrosis factor prevents myocardial dysfunction during burn shock. Am J Physiol. 267:1994;H118-H124.
31. Fisher C.J., Agosi J.M., Opal S.M.et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med. 334:1996;1697-1702.